Ron Alfa

Founder

Now Founder, Noetik

Latest on AI4S.fyiTimeline · Jun 15Noetik's TARIO-2 picked out likelier responders to Agenus's BOT+BAL immunotherapy from routine biopsy slides, looking back at 49 colorectal cancer patients in a trial

Account links back to noetik.ai · Avatar from their X account, taken 2026-09-28

Affiliations

Current

Founder · Noetikbiospace.com ↗

Also named in the companies' announcements: Recursion

Current roles come from these dated records, not from the bio below. Each links the page it was read from.

About

Ron Alfa is co-founder and chief executive of Noetik, a cancer drug discovery company that builds machine learning models on its own human tumour data. Before Noetik he was senior vice president and head of research at Recursion, where he was an early employee from its seed round through its IPO. He holds an MD and a PhD in neuroscience from Stanford.

Read on 2026-09-29; for current roles see Affiliations above. Read at: noetik.ai ↗ · biospace.com ↗

Founded

NoetikDrug discovery · 2 rounds on record · disclosed $54M · Series A $40M
Background: Recursion (executive) (as the company's own announcements put it)
Co-founders: Jacob Rinaldi
Backed byPolaris Partners DCVC

On the timeline

2026-06-15Noetik's TARIO-2 picked out likelier responders to Agenus's BOT+BAL immunotherapy from routine biopsy slides, looking back at 49 colorectal cancer patients in a trial

Something wrong or missing on this page? Tell me and it will be fixed or removed. Contact →